We are a clinical-stage biotechnology company focused primarily on developing novel pharmaceuticals to treat cardiometabolic diseases. We have two programs focused primarily on the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and obesity. ● Vanoglipel (DA-1241) is a novel GPR119 (“GPR119”) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (“ T2DM”).
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Dong-A ST (related party; exclusive global license ex-Korea under 2022 License Agreement)
Indications
obesity(Stage not disclosed)
metabolic dysfunction-associated steatohepatitis (potential)(Stage not disclosed)
Catalysts
— None
Status note First-in-human Phase 1 trial initiated 2024; Parts 3a/3b titration studies started April 2026 with dose titration completed July 2026. Dose titration studies designed to improve tolerability and enable higher dose levels.
vanoglipel
Phase 2 · Active
Aliases DA-1241
Target GPR119
Partnerships Dong-A ST (related party; exclusive global license ex-Korea under 2022 License Agreement; may also develop for type 2 diabetes)
Indications
metabolic dysfunction-associated steatohepatitis (MASH)(Stage not disclosed)
Catalysts
— None
Status note Phase 2a first-in-human MASH trial initiated 2023. Company expects to discuss development pathway for a vanoglipel combination therapy.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.